Abstracts Archive - Page 989 of 2425 - ACR Meeting Abstracts

Abstract Number: 520 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 522 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
Thierry Sornasse¹, Jeremy Sokolove ¹ and Iain McInnes ², ¹AbbVie Immunology Clinical Development, Redwood City, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
Abstract Number: 523 • 2019 ACR/ARP Annual Meeting
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Ronald van Vollenhoven¹, Andrew Östör ², Eduardo Mysler ³, Nemanja Damjanov ⁴, In-Ho Song ⁵, Yanna Song ⁶, Jessica Suboticki ⁵ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ³Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In Phase 3 trials, upadacitinib (UPA), an oral JAK1-selective inhibitor, has been assessed as monotherapy vs MTX (SELECT-EARLY1) and in combination with MTX vs…
Abstract Number: 524 • 2019 ACR/ARP Annual Meeting
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
Joel Kremer¹, Filip Van den Bosch ², Andrea Rubbert-Roth ³, Sebastiao Radominski ⁴, Gerd Burmester ⁵, Heidi Camp ⁶, Sebastian Meerwein ⁷, Mark Howard ⁸, Yanna Song ⁹, Sheng Zhong ¹⁰ and Bernard Combe ¹¹, ¹Albany Medical College, Albany, NY, ²Ghent University Hospital, Ghent, Belgium, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Charité—University Medicine Berlin, Berlin, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc., North Chicago, IL, USA, North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
Abstract Number: 525 • 2019 ACR/ARP Annual Meeting
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis
Larissa Valor¹, Melanie Hagen ², Michaela Reiser ³, Fabian Hartmann ³, Arnd Kleyer ², Bernhard Manger ⁴, Georg Schett ⁵, Jürgen Rech ⁶ and Koray Tascilar ⁷, ¹Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany
Background/Purpose: Persistent drug-free remission of RA is a condition close to “cure” of the disease. Long-term drug-free remission is considered rare and challenging to reach,…
Abstract Number: 526 • 2019 ACR/ARP Annual Meeting
Factors Influencing Discontinuation in Long-term RA Treatment
Madison Grinnell¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
Abstract Number: 527 • 2019 ACR/ARP Annual Meeting
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Roy Fleischmann¹, Jose Jeffrey Enejosa ², In-Ho Song ³, Eduardo Mysler ⁴, Louis Bessette ⁵, Charles Peterfy ⁶, Patrick Durez ⁷, Andrew Östör ⁸, Yijie Zhou ⁹ and Mark Genovese ¹⁰, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Laval University, Quebec City, QC, Canada, ⁶Spire Sciences Inc, Boca Raton, ⁷Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁸Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁹AbbVie Inc., North Chicago, ¹⁰Stanford University, Stanford, CA
Background/Purpose: In the SELECT-COMPARE study in rheumatoid arthritis (RA) patients (pts) with inadequate response to methotrexate (MTX), upadacitinib (UPA), a JAK1- selective inhibitor, was superior…
Abstract Number: 528 • 2019 ACR/ARP Annual Meeting
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Daniel Furst ², Erin Connolly-Strong ³, Jingyu Liu ³, Julie Zhu ³ and Richard Brasington ⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Washington University School of Medicine in St Louis, St Louis, MO
Background/Purpose: Persistently active rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and bone loss.1 Although short-term administration of corticosteroids (CSs) is recommended…
Abstract Number: 529 • 2019 ACR/ARP Annual Meeting
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
Stephen Hall¹, Tsutomu Takeuchi ², Glen Thomson ³, Paul Emery ⁴, Bernard Combe ⁵, Andrea Everding ⁶, Karel Pavelka ⁷, Yanna Song ⁸, Tim Shaw ⁹, Alan Friedman ⁹, In-Ho Song ¹⁰ and Eduardo Mysler ¹¹, ¹Monash University and Emeritus Research, Melbourne, Australia, ²Keio University School of Medicine, Tokyo, Japan, ³CIADS Research, Winnipeg, Canada, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵CHU Montpellier, Montpellier University, Montpellier, France, ⁶HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁹AbbVie Inc., North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO)…
Abstract Number: 530 • 2019 ACR/ARP Annual Meeting
Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Daniel Dairaghi¹, Karen Cox ¹, Stephen Ho ¹, Paul Klekotka ², Diane Phillips ¹, Jean Lim ³, Shweta Urva ¹ and Dipak Patel ², ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, singapore, Singapore
Background/Purpose: LY2775240 is a potent and selective phosphodiesterase (PDE4) inhibitor being investigated as a potential treatment for inflammatory disorders, such as psoriasis. PDE4 is expressed…
Abstract Number: 531 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Anita Kass¹, Hans Christian Gulseth ¹ and Camilla Zettel ¹, ¹Betanien Hospital, Skien, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
Abstract Number: 532 • 2019 ACR/ARP Annual Meeting
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Hayato Hisaki ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 533 • 2019 ACR/ARP Annual Meeting
Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients
Jennifer Schenfeld¹, Scott Stryker ², Hafiz Oko-osi ¹ and Bradley Stolshek ², ¹Amgen, Inc, Thousand Oaks, CA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Changes in formulary tiers can potentially have unintended impact on outcomes. Moderate-to-severe rheumatoid arthritis (RA) is often treated with Tumor Necrosis Factor inhibitors (TNFi).…
Abstract Number: 534 • 2019 ACR/ARP Annual Meeting
CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
Silvia Piantoni¹, Francesca Regola ², Laura Andreoli ³, Angela Tincani ³ and Paolo Airò ⁴, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ⁴UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: CXCL13 chemokine, by interacting with CXCR5 receptor, attracts B-lymphocytes and CD4+CXCR5+ICOS+ follicular helper T-lymphocytes (THFs) in lymphoid follicles. In rheumatoid arthritis (RA) CXCL13 is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].